Oxler Private Wealth LLC Acquires 28 Shares of Eli Lilly and Company (NYSE:LLY)

Oxler Private Wealth LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.5% during the third quarter, HoldingsChannel reports. The firm owned 6,050 shares of the company’s stock after buying an additional 28 shares during the period. Eli Lilly and Company comprises 1.9% of Oxler Private Wealth LLC’s portfolio, making the stock its 17th biggest holding. Oxler Private Wealth LLC’s holdings in Eli Lilly and Company were worth $5,360,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. ORG Wealth Partners LLC purchased a new position in Eli Lilly and Company during the third quarter valued at approximately $1,187,000. Woodstock Corp boosted its stake in Eli Lilly and Company by 1.5% during the third quarter. Woodstock Corp now owns 8,151 shares of the company’s stock valued at $7,221,000 after buying an additional 122 shares during the last quarter. Svenska Handelsbanken AB publ purchased a new position in Eli Lilly and Company during the 3rd quarter valued at approximately $33,172,000. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its stake in Eli Lilly and Company by 2.6% in the 3rd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 64,775 shares of the company’s stock worth $57,387,000 after acquiring an additional 1,614 shares during the last quarter. Finally, Sunflower Bank N.A. raised its holdings in shares of Eli Lilly and Company by 1.7% during the 3rd quarter. Sunflower Bank N.A. now owns 1,744 shares of the company’s stock worth $1,545,000 after acquiring an additional 29 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $2.75 during midday trading on Monday, hitting $929.31. The company had a trading volume of 248,903 shares, compared to its average volume of 2,995,509. The company has a fifty day simple moving average of $910.84 and a 200 day simple moving average of $853.38. The stock has a market cap of $883.22 billion, a price-to-earnings ratio of 137.27, a PEG ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on LLY shares. Citigroup initiated coverage on shares of Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective for the company. Berenberg Bank boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Jefferies Financial Group raised their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Finally, Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $979.29.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.